AxoGen (AXGN) Given a $37.00 Price Target by Cantor Fitzgerald Analysts

AxoGen (NASDAQ:AXGN) has been given a $37.00 price target by equities research analysts at Cantor Fitzgerald in a research note issued on Monday. The firm presently has a “buy” rating on the medical equipment provider’s stock. Cantor Fitzgerald’s price target would suggest a potential upside of 32.14% from the company’s current price. Cantor Fitzgerald also issued estimates for AxoGen’s FY2017 earnings at ($0.31) EPS and FY2018 earnings at ($0.27) EPS.

A number of other research firms have also issued reports on AXGN. Leerink Swann boosted their price objective on AxoGen from $26.00 to $30.00 and gave the company an “outperform” rating in a research note on Tuesday, November 21st. Lake Street Capital boosted their price objective on AxoGen from $22.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, November 21st. Roth Capital reiterated a “buy” rating and set a $21.00 price objective (up from $18.00) on shares of AxoGen in a research note on Tuesday, September 12th. Wedbush reiterated a “buy” rating and set a $27.00 price objective (up from $22.00) on shares of AxoGen in a research note on Tuesday, November 21st. Finally, Jefferies Group started coverage on AxoGen in a research note on Thursday, November 30th. They set a “buy” rating and a $35.00 price objective on the stock. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The company has an average rating of “Buy” and an average price target of $29.33.

Shares of AxoGen (AXGN) traded down $1.40 on Monday, hitting $28.00. The company’s stock had a trading volume of 669,300 shares, compared to its average volume of 474,867. The company has a market capitalization of $1,000.00, a price-to-earnings ratio of -66.67 and a beta of 0.89. The company has a debt-to-equity ratio of 1.93, a quick ratio of 2.95 and a current ratio of 3.55. AxoGen has a 52-week low of $8.75 and a 52-week high of $31.70.

AxoGen (NASDAQ:AXGN) last issued its earnings results on Wednesday, November 1st. The medical equipment provider reported ($0.06) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.06). The firm had revenue of $16.05 million for the quarter, compared to analyst estimates of $15.55 million. AxoGen had a negative return on equity of 91.00% and a negative net margin of 24.74%. The firm’s revenue was up 43.2% on a year-over-year basis. equities analysts forecast that AxoGen will post -0.31 EPS for the current year.

In related news, Director Jamie Mark Grooms sold 21,290 shares of the business’s stock in a transaction dated Wednesday, December 6th. The stock was sold at an average price of $26.22, for a total transaction of $558,223.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Guido J. Neels sold 1,150,000 shares of the business’s stock in a transaction dated Monday, November 20th. The stock was sold at an average price of $19.74, for a total value of $22,701,000.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,293,990 shares of company stock worth $26,494,898. 9.33% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently bought and sold shares of AXGN. Schwab Charles Investment Management Inc. grew its position in AxoGen by 33.9% during the second quarter. Schwab Charles Investment Management Inc. now owns 51,300 shares of the medical equipment provider’s stock worth $860,000 after buying an additional 13,000 shares in the last quarter. Rhumbline Advisers grew its position in AxoGen by 11.4% during the second quarter. Rhumbline Advisers now owns 28,720 shares of the medical equipment provider’s stock worth $481,000 after buying an additional 2,945 shares in the last quarter. Bank of New York Mellon Corp grew its position in AxoGen by 80.7% during the second quarter. Bank of New York Mellon Corp now owns 160,354 shares of the medical equipment provider’s stock worth $2,685,000 after buying an additional 71,609 shares in the last quarter. Neuberger Berman Group LLC purchased a new position in AxoGen during the second quarter worth about $201,000. Finally, Wells Fargo & Company MN grew its position in AxoGen by 17.2% during the second quarter. Wells Fargo & Company MN now owns 46,745 shares of the medical equipment provider’s stock worth $783,000 after buying an additional 6,848 shares in the last quarter. Institutional investors and hedge funds own 66.00% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This report was first reported by Community Financial News and is owned by of Community Financial News. If you are viewing this report on another domain, it was copied illegally and reposted in violation of United States & international trademark and copyright laws. The legal version of this report can be accessed at https://www.com-unik.info/2018/01/10/axogen-axgn-given-a-37-00-price-target-by-cantor-fitzgerald-analysts.html.

AxoGen Company Profile

AxoGen, Inc provides surgical solutions for peripheral nerve injuries. The company’s surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.

Analyst Recommendations for AxoGen (NASDAQ:AXGN)

Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit